New Braasch Biotech vaccine technology provides Growth Hormone and IGF-1 treatments without the use of drugs.

Braasch Biotech LLC (Braasch) announces its lead vaccine for Obesity, Growth Hormone Deficiencies may have beneficial use for numerous IGF-1 responsive disorders such as diabetes, heart disease and Rett Syndrome based on initial pre-clinical testing in a mouse model. A new vaccine technology that stimulates the body to release more of its own Growth Hormone (GH) and Insulin Growth Factor 1 (IGF-1) is expected to open a new world of treatment options for growth hormone deficiencies, obesity, specific types of diabetes as well as for a potentially long list of IGF-1 responsive neurological disorders. Braasch has successfully created a vaccine technology specifically designed to generate a …